Oral Fexinidazole Dosing Regimens for the Treatment of Adults With Chronic Indeterminate Chagas Disease (FEXI12)

September 21, 2020 updated by: Drugs for Neglected Diseases

Phase 2 Randomized, Multicenter, Double-blinded Safety and Efficacy Study to Evaluate Oral Fexinidazole Dosing Regimens for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease

This study focuses on the evaluation of low doses (600 and 1200 mg) and short treatment duration (at 3, 7 and 10 days) of fexinidazole (Fexi) to determine the minimal efficacious and safe dose for the treatment of adult patients with chronic indeterminate Chagas Disease (CD).

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Fexi anti-protozoal activity against T. cruzi has been demonstrated by various in vitro and in vivo studies.

Patients will be randomly assigned to receive one of three different treatment regimen arms containing either the active drug or matching placebo tablet

Following conclusion of 12 months of follow-up of DNDi-CH-FEXI-001 clinical trial, unblinded data review showed high sustained parasite clearance rates of FEXI even at the lowest dose tested (1200 mg 2 weeks), including in patients that received < 3days treatment.

Study Type

Interventional

Enrollment (Actual)

45

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Spain
    • Catalunia
      • Barcelona, Catalunia, Spain, 08036
        • Hospital Clinic

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Screening Criteria:

  • Signed, written informed consent form
  • Age >18 to < 60 years
  • Weight > 50 kg to < 90 kg
  • Diagnosis of T. cruzi infection by:
  • Conventional serology (a minimum of two positive tests [Conventional ELISA, Recombinant Elisa, Chemiluminescence Immunoassays and/or Indirect Immunofluorescence (IIF)]
  • Ability to comply with all protocol specified tests and visits and have a permanent address
  • No signs and/or symptoms of the chronic cardiac and/or digestive form of Chagas Disease (CD) (as per study operating procedures)
  • No personal history of mental disability or suicidal tendencies
  • No acute or chronic health conditions, that in the opinion of the PI, may interfere with the efficacy and/or safety evaluation of the trial drug (such as acute infections, history of HIV infection, liver, and renal disease requiring treatment)
  • No formal contraindication to FEXI (according to the latest available Investigator's Brochure)
  • No history of hypersensitivity, allergic, or serious adverse reactions to any of the "nitro-imidazoles" compound, and/or its components
  • No history of CD treatment with BZN, FEXI or Nifurtimox (NFX) at any time in the past
  • No history of alcohol abuse or any other drug addiction (as per Study Manual of Operations)
  • No condition that prevents patient from taking oral medication
  • No concomitant medication with drug known risk of Torsade de Pointe, according AZCERT Scientific Publications and Sudden Arrhythmia Death Syndromes Foundation (SADS Foundation) (https://www.crediblemeds.org/index.php/new-drug-list)
  • No family history of sudden death
  • No family history of sudden infant death syndrome

Inclusion Criteria:

Following the screening period, patients must also meet all of the following inclusion criteria to be eligible for randomization:

  • Confirmed diagnosis of T. cruzi infection by:
  • Serial qualitative PCR (three samples collected over a single day, at least one of which must be positive),

and

  • Conventional serology (a minimum of two positive tests must be positive, Conventional ELISA, Recombinant Elisa, Chemiluminescence immunoassays and/or IIF)
  • Women in reproductive age must have a negative serum pregnancy test at screening, must not be breastfeeding, must consistently use a highly effective contraceptive method until end of treatment and estimated FEXI, M1 and M2 clearance (total of 21 days). After this, contraception is no longer required.
  • Normal ECG (Heart rate: 50-100bpm; PR interval ≤200 msec, QRS complex ≤120 msec, and QT interval corrected for heart rate (QTc) ≥350msec and ≤450 msec interval durations) at screening
  • 24 hour Holter-monitoring with no clinically relevant arrythmias (defined as Ventricular Tachycardia (defined as >3 ventricular beats with >100bpm); Sustained Accelerated Idio-Ventricular rhythm (defined as >30 seconds duration and Heart Rate (HR): 50bpm<HR<100bpm); frequent Ventricular Premature Beats (10/hour); Atrial Fibrillation/flutter; Mobitz type 2 second degree AV block; High degree and complete AV block; Bradycardia episodes <40bpm)

Exclusion Criteria:

  • Signs and/or symptoms of chronic cardiac and/or digestive form of CD (as per Study Manual of Operations).
  • History of cardiomyopathy, heart failure, or ventricular arrhythmia.
  • History of digestive surgery or mega syndromes.
  • Personal history of mental disability or suicidal tendencies
  • Hospital Anxiety and Depression Scale (HADS - Appendix 1) self-assessment score >11 in each of the sub-scales. (Note: If HADS score >11, retesting would be allowed before after a minimum period of 15 days and referral to counseling/evaluation.)
  • Any other acute or chronic health conditions that, in the opinion of the PI, may interfere with the efficacy and/or safety evaluation of the trial drug (such as acute infections, history of HIV infection, diabetes, uncontrolled systolic/diastolic blood pressure, liver, and renal diseases requiring medical treatment).

  • Laboratory test values considered clinically significant or out of the allowable range at selection period as follows:

    • Total White Blood Count (WBC) must be within the normal range, with an acceptable margin of +/- 5% (3,800 - 10,500 / mm3).
    • Platelets must be within the normal range up to 550,000/mm3
    • Total bilirubin must be within the normal range
    • Transaminases (ALT and AST) must be within the normal range, with an acceptable margin of 25% above the upper limit of normality (ULN), < 1.25 x ULN.
    • Creatinine must be within an acceptable margin of 10% above the ULN, <1.10 x ULN.
    • Alkaline phosphatase must be within the normal range up to Grade 1 CTCAE (<,2.5 x ULN)
    • Gamma-glutamyl Transpeptidase (GGT) must be within the normal range up to 2x ULN.
    • Fasting glucose (minimum of 8 hours from latest meal) must be within the normal range
    • Electrolytes (Ca, Mg, K) must be within the normal range
    • Hepatitis screen must be negative for acute and/or chronic infection (Hepatitis A antibody, Imunoglobulina M (IgM); Hepatitis B surface Ag, Hepatitis B

If the results of the blood tests (hematology and biochemistry) are out of the ranges defined above, but within the limits of CTCAE (version 4.03) Grade 1, and this laboratory finding is considered as non-clinically significant, a new sample can be collected for a retest. Only one retest will be allowed within the screening period.

If the result of the retest is within the margins defined above, the Investigator will review the parameter(s) together with all other medical information available (medical history, clinical examinations, vital signs, etc.) and upon his/her medical judgement will decide if the patient is eligible or not for trial randomization.

Any condition that prevents the patient from taking oral medication.

  • Patients with any contra-indication (known hypersensitivity) to any nitroimidazoles, e.g. metronidazole
  • Patients with history of allergy (serious or not), allergic skin rash, asthma, intolerance, sensitivity or photosensitivity to any drug
  • Any concomitant use of allopurinol, antimicrobial, anti-parasitic agents, and/or of herbal medicines, food supplements and energetic drinks
  • Any concomitant medication with drug known risk of Torsade de Pointe, according AZCERT Scientific Publications and SADS Foundation (www.crediblemeds.org/index.php/new-drug-list)
  • Any planned surgery likely to interfere with the trial conduction and/or treatment evaluation
  • Unlikely to return for study visits, comply with study treatment and co-operate with the trial-related procedures.
  • Any previous participation in any clinical trial for Chagas Disease treatment evaluation
  • Participation in another trial at the same time or within 3 months prior to selection (according to local regulations).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group A
Fexinidazole (FEXI) 600 mg x 10 days in a single daily dose orally (1 fexinidazole 600 mg tablet and 1 fexinidazole matching placebo oral tablet administered in a single daily dose) (total dose: 6.0 g).
Drug: Fexinidazole
Drug: fexinidazole (FEXI)
Other Names:
  • FEXI
Drug: Placebo Oral Tablet
Drug: fexinidazole
Other Names:
  • Placebo
Experimental: Group B
Fexinidazole (FEXI) 1200 mg x 3 days orally (2 fexinidazole 600 mg tablets administered in a single daily dose for 3 days), to be followed by matching placebo oral tablet for 7 days (2 fexinidazole matching placebo oral tablets administered once daily for 7 days) (total dose: 3.6 g).
Drug: Fexinidazole
Drug: fexinidazole (FEXI)
Other Names:
  • FEXI
Drug: Placebo Oral Tablet
Drug: fexinidazole
Other Names:
  • Placebo
Experimental: Group C
Fexinidazole (FEXI) 600 mg for 3 days, followed by 1200 mg in a single daily dose orally for 4 days (1 fexinidazole 600 mg tablet AND 1 fexinidazole matching placebo oral tablet administered in a single daily dose for 3 days, to be followed by 2 fexinidazole 600 mg tablets for 4 days), then followed by matching placebo oral tablet for 3 days (2 fexinidazole matching placebo tablets administered once daily for 3 days) (total dose: 6.6 g).
Drug: Fexinidazole
Drug: fexinidazole (FEXI)
Other Names:
  • FEXI
Drug: Placebo Oral Tablet
Drug: fexinidazole
Other Names:
  • Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Incidence and severity of adverse events.
Time Frame: 12 months
12 months

Secondary Outcome Measures

Outcome Measure
Time Frame
Pharmacokinetic : measure of blood concentration of fexinidazole, fexinidazole sulfoxide and fexinidazole sulfone in order to determine AUC0-t values, for all dose levels.
Time Frame: D0 (pre-dose), Day 1, Day 2, Day 3, and at steady-state phase (week 2-10).
D0 (pre-dose), Day 1, Day 2, Day 3, and at steady-state phase (week 2-10).
Pharmacokinetic : measure of blood concentration of fexinidazole, fexinidazole sulfoxide and fexinidazole sulfone in order to determine Cmax values, for all dose levels.
Time Frame: D0 (pre-dose), Day 1, Day 2, Day 3, and at steady-state phase (week 2-10).
D0 (pre-dose), Day 1, Day 2, Day 3, and at steady-state phase (week 2-10).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Drugs for Neglected Diseases

Investigators

  • Principal Investigator: Joaquim Gascón, MD, Centro de Salud Internacional, Hospital Clínico de Barcelona ISGlobal - Barcelona Institute for Global Health

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 13, 2017

Primary Completion (Actual)

December 19, 2018

Study Completion (Actual)

August 28, 2019

Study Registration Dates

First Submitted

April 27, 2018

First Submitted That Met QC Criteria

July 3, 2018

First Posted (Actual)

July 16, 2018

Study Record Updates

Last Update Posted (Actual)

September 23, 2020

Last Update Submitted That Met QC Criteria

September 21, 2020

Last Verified

September 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • DNDi-FEX-12-CH
  • 2016-004905-15 (EudraCT Number)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Yes

IPD Plan Description

Not yet decided how Individual Participant Data (IPD) will be shared, This action is under internal review within DNDi.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chagas' Disease (Chronic) Nos

Clinical Trials on Fexinidazole

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Morocco

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe